Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.

Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

GSK annual report says China bribery case spawned surge in compliance 'contacts'

It turns out the GlaxoSmithKline whistleblowers who blew the top off the China corruption scandal had hundreds of copycats later on.

GSK CEO Witty's pay whacked as U.K.'s largest drugmaker struggles to right itself

2014 was a tough year for GlaxoSmithKline. Its revenues and profits were off significantly. Its operating profit was off nearly 50% in pounds--and, as it turns out, so was CEO Andrew Witty's pay. In fact he took a 46% whack to his compensation.

GlaxoSmithKline's new chairman will climb aboard months earlier than expected

GlaxoSmithKline says Sir Philip Hampton is free to take the reins in May.

Sidelined after tampering incident, GSK's alli is back on sale

After nearly a year off the shelves, GlaxoSmithKline's diet pill alli--recalled after reports of tampering--is back in most U.S. stores, and it's got some updates that should make any future tampering easier to spot.

UPDATED: NIH funds studies of J&J's and GSK's injectable HIV meds, says daily pills lead to noncompliance

In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.

Lupin inks two partnerships to bring lung drugs to overseas markets

Indian drugmaker Lupin announced two separate developments in its asthma drug delivery segment, launching one product in the U.S. and signing a development agreement for a generic version of GlaxoSmithKline's Advair Diskus, which would be commercialized in North America and other markets.

AstraZeneca picks outspoken (and sometimes critical) prof to join board

Just who is the neuroscientist and university professor AstraZeneca has nominated to its board of directors? A sometime critic of the pharma industry, the  Financial Times  points out.

Heard it on the biotech grapevine? Drop me a line

Whether it's a reorg at a big company like Sanofi or GlaxoSmithKline, or a biotech like Constellation, I rely quite a bit on the big global network of readers we've gathered over the past 13 years to keep me posted on the things that companies don't put in a press release.

Lupin, WuXi PharmaTech, Integrity Applications: Asia Company News

FiercePharmaAsia rounds up company activity in Asia across pharmaceuticals, biotech and devices to stay abreast of deal making and provide insight on partnerships and disputes in the works.

Shanghai official linked to GSK bribery sentenced to 19 years in prison

The GlaxoSmithKline officials accused of orchestrating its $489 million Chinese bribery scandal may have dodged prison sentences in the country, but a Shanghai health official linked to the British pharma won't be so lucky.